Accuri Cytometers Completes $6 Million Series E Financing
ANN ARBOR - Accuri Cytometers said Monday the company has completed a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse. Accuri plans to use the proceeds from the Series E financing to support expansion